Conart Engineers Secures ₹14.50 Crore Civil Work Order for M/s. Apothecon Pharmaceuticals Facility

Team FS

    05/Sep/2024

What's covered in the Article:

Conart Engineers has been awarded a civil construction project for M/s. Apothecon Pharmaceuticals worth ₹14.50 crore.

The construction will be completed within 11 months at the Vadodara site.

The company has closed its trading window for insiders as per SEBI regulations following the project announcement.

In an exciting development for the construction sector, Conart Engineers Limited has announced that it has secured a prestigious order for the civil construction of a formulation facility for M/s. Apothecon Pharmaceuticals Pvt. Ltd. The project, valued at ₹14.50 crore, including GST, will be executed in Vadodara, Gujarat. This major contract win underscores Conart Engineers' growing prominence in delivering high-quality civil engineering services.

The construction work will commence upon mobilization at the site and is expected to be completed within 11 months. This time-sensitive project will be instrumental in expanding Apothecon Pharmaceuticals' manufacturing capabilities, allowing them to produce formulations more efficiently.

Key Project Details

The project involves the construction of a formulation facility, which is a critical component for the pharmaceutical industry. This will be handled by Conart Engineers, a company known for its expertise in civil engineering and construction management. With a track record of delivering large-scale infrastructure projects, Conart Engineers is well-equipped to meet the stringent demands of this assignment.

Project Specifications:

Project Cost (Including GST): ₹14.50 crore

Location: Vadodara, Gujarat

Scope of Work: Civil work for the formulation facility

Completion Timeline: 11 months from mobilization at the site

The contract reflects Conart Engineers' ability to secure and deliver high-value projects in diverse industries, including pharmaceuticals, which is vital for India's growing healthcare and manufacturing sectors. This partnership with Apothecon Pharmaceuticals Pvt. Ltd. is expected to strengthen the company’s portfolio in the industrial construction segment.

Compliance with Insider Trading Regulations

In accordance with SEBI's (Prohibition of Insider Trading) Regulations, Conart Engineers has also announced the closure of its trading window. This policy applies to all insiders, designated persons, and their immediate families to prevent any unlawful trading based on this sensitive information. The trading window will remain closed until 48 hours after this information is made public, ensuring full compliance with the regulatory framework.

Conart Engineers Limited, with its visionary leadership and strong execution capabilities, continues to position itself as a leader in the civil engineering and construction sector. By consistently delivering projects within the specified timelines and to the highest quality standards, the company remains committed to its mission of engineering excellence.

For more updates on corporate projects, visit:
Best IPO to Apply Now - IPO List 2024, Latest IPO, Upcoming IPO, Recent IPO News, Live IPO GMP Today - Finance Saathi
Top News Headlines - Share Market News, Latest IPO News, Business News, Economy News - Finance Saathi

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst & Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

This project is another milestone for Conart Engineers as it continues to grow its portfolio of complex construction projects across India. Keep following for more updates on new projects and announcements in the construction and civil engineering space.

Related News

Disclaimer

The information provided on this website is for educational and informational purposes only and should not be considered as financial advice, investment advice, or trading recommendations.

Trading in stocks, forex, commodities, cryptocurrencies, or any other financial instruments involves high risk and may not be suitable for all investors. Prices can fluctuate rapidly, and there is a possibility of losing part or all of your invested capital.

We do not guarantee any profits, returns, or outcomes from the use of our website, services, or tools. Past performance is not indicative of future results.

You are solely responsible for your investment and trading decisions. Before making any financial commitment, it is strongly recommended to consult with a qualified financial advisor or do your own research.

By accessing or using this website, you acknowledge that you have read, understood, and agree to this disclaimer. The website owners, partners, or affiliates shall not be held liable for any direct or indirect loss or damage arising from the use of information, tools, or services provided here.

onlyfans leakedonlyfan leaksonlyfans leaked videos